Cortex Pharmaceuticals Inc.
The Irvine drug development company’s losses in the fiscal first quarter ended Sept. 30 widened to $1.2 million, or 16 cents a share, from $954,610, or 16 cents a share, a year ago. No revenue was reported.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
